Research Focus: Targeting the MCL-1 Pathway With CDK9 Inhibitors in AML

In this slideset and commentary, I explore the novel approach of inhibiting CDK9 as a way of downregulating MCL-1 and thereby minimizing survival signals in AML cells.

Eunice S. Wang, MD

Certified Slideset

In this CME-certified slideset, CCO’s expert faculty describes the rationale for targeting MCL-1 with CDK9 inhibitors in AML and discusses preclinical studies and early clinical trials of investigational CDK9 inhibitors.

Eunice S. Wang, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: May 3, 2019 Expired: No longer available for credit
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Boston Biomedical, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue